Role of serotonergic system on modulation of depressogenic-like effects of silymarine

Iranian Journal of Pharmaceutical Research

Volumn 11, Issue 1, 2012, Pages 331-337

  Yaghmaei, Parichehr ^a   Oryan, Shahrbanoo ^b   Mohammadi, Khadijeh ^a   Solati, Jalal ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

5HT1A; Depression; Rat; Serotonin; Silymarine

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; SEROTONIN 1A RECEPTOR; SILYMARIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; NONHUMAN; RAT; SEROTONINERGIC SYSTEM;

EID: 84858589259     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Keller M, McCullough J, Klein D, Arnow B, Dunner D, Gelenberg A, Markowitz J, Nemeroff C, Russell J and Thase M. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. New Engl. J. Med. (2000) 342: 1462.
2. Beck A and Alford B. Depression: Causes and Treatment. Univ of Pennsylvania Pr, (1972) 11-23.
3. Comstock G and Helsing K. Symptoms of depression in two communities. Psychol. Med. (2009) 6: 551-563.
4. Davis L, Bartolucci A and Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J. Affective Disorders (2005) 85: 259-266.
5. Schlaepfer T, Cohen M, Frick C, Kosel M, Brodesser D, Axmacher N, Joe A, Kreft M, Lenartz D and Sturm V. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology (2007) 33: 368-377.
6. Abraham G, Milev R and Stuart Lawson J. T3 augmentation of SSRI resistant depression. J. Affective Disorders (2006) 91: 211-215.
7. Kessler R, Soukup J, Davis R, Foster D, Wilkey S, Van Rompay M and Eisenberg D. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am. J. Psychiatry (2001) 158: 289.
8. Eisenberg D, Davis R, Ettner S, Appel S, Wilkey S, Van Rompay M and Kessler R. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA (1998) 280: 1569.
9. Astin J. Why patients use alternative medicine: results of a national study. JAMA (1998) 279: 1548.
10. Seeff L, Lindsay K, Bacon B, Kresina T and Hoofnagle J. Complementary and alternative medicine in chronic liver disease. Hepatology (2001) 34: 595-603.
11. Verma S and Thuluvath P. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin. Gastroenterol. Hepatol. (2007) 5: 408-416.
12. Moulisov V and Jegorov A. Silymarin flavonoids and cyclosporin A: Effective co-therapy. Iranian J. Pharm. Res. (2004) 3: 12-12.
13. Khalilian A, Saffary N, Rahmani N and Eskandary S. Optimization of extraction of Silybum marianum fruits, presentation of three formulations of its active chemicals and designing a dissolution test method for silymarin tablet. Iranian J. Pharm. Res. (2004) 3: 47-47.
14. Pradhan SC andGirish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J. Med Res. (2006) 124: 491-504.
15. Lu P, Mamiya T, Lu L, Mouri A, Niwa M, Kim H, Zou L, Nagai T, Yamada K and Ikejima T. Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. Behav. Brain Res. (2009) 387-93.
16. Savitz J, Lucki I and Drevets W. 5-HT1A receptor function in major depressive disorder. Prog. Neurobiol. (2009) 88: 17-31.
17. Pucadyil T, Kalipatnapu S and Chattopadhyay A. The serotonin 1A a receptor: a representative member of the serotonin receptor family. Cell. Mol. Neurobiol. (2005) 25: 553-580.
18. Paxinos G. The Rat Brain in Stereotaxic Coordinates. Elsevier Academic Press, San Diego (2007) 51-55.
19. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav. Pharmacol. (1997) 8: 523.
20. Roy-Byrne P and Bystritsky A, Russo J, Craske M, Sherbourne C and Stein M. Use of herbal medicine in primary care patients with mood and anxiety disorders. Psychosomatics (2005) 46: 117.
21. Drew A and Myers S. Safety issues in herbal medicine: implications for the health professions. Med. J. Aus. (1997) 166: 538-544.
22. Ernst E, Rand J, Barnes J and Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur. J. Clin. Pharmacol. (1998) 54: 589-594.
23. Srinivas B, Subhash M and Vinod K. Cortical 5-HT1A receptor downregulation by antidepressants in rat brain. Neurochem. Int. (2001) 38: 573-579.
24. Stahl S. 5HT1A receptors and pharmacotherapy. Is serotonin receptor down-regulation linked to the mechanism of action of antidepressant drugs? Psychopharmacol. Bull. (1994) 30: 39.
25. Blier P and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. (1994) 15: 220-226.
26. Blier Pand Ward N. Is there a role for 5-HT1A agonists in the treatment of depression? Biol. Psychiatry (2003) 53: 193-203.
27. Paul RA and Lemonde S. Lemonde S. 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist (2004) 10: 575.